TSLPR-directed CAR T
/ Fred Hutchinson Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 05, 2021
Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML
(ASH 2021)
- "We further demonstrate that CAR T cells targeting TSLPR were effective in eliminating AML cells in vitro and in vivo . Given that TSLPR is highly expressed in the KMT2A-rearranged AML, a subtype that is associated with poor outcomes, TSLPR-directed CAR T cells represent a promising immunotherapy for this high-risk AML subset."
CAR T-Cell Therapy • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • Transplantation • CRLF2 • KMT2A
1 to 1
Of
1
Go to page
1